Johnson & Johnson's Q1 2010 earnings report presents a mixed outlook for short-term stock performance. While the company experienced operational sales growth and margin improvement, the impact of healthcare reform, product recalls (OTC), and ongoing litigation could pressure its stock price. Cost-saving measures and growth in segments like medical devices signal resilience, but the immediate hit from healthcare reforms might overshadow these positives in the near term. 

[-1]